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We analysed the risk of cutaneous malignant melanoma (CM) occurring in patients following a diagnosis of non-Hodgkin’s lymphoma
(NHL) or chronic lymphatic leukaemia (CLL), and of NHL or CLL subsequently developing in CM survivors. Cohorts of patients with
CM, NHL or CLL (index cancer) diagnosed between 1975 and 1997 were identified from the Scottish national cancer registry and
followed through the registry for subsequent CM, NHL or CLL. The standardised incidence ratio (SIR) for each cancer was calculated
and overall risk, risk in relation to gender and age at diagnosis of the index cancers and time from diagnosis of the index cancer to the
diagnosis of the second malignancy were measured. There were 9385 CM patients, 4016 CLL patients and 13857 NHL patients
identified with an index cancer with 56195, 14450 and 44999 person-years of follow-up, respectively. There was an increased risk of
both CLL and NHL following a diagnosis of CM (SIR 2.3 and 1.5, respectively) and of CM following a diagnosis of CLL and NHL (SIR
2.3 and 2.1, respectively). The risk was statistically significantly increased for CLL developing in CM patients and for CM occurring in
NHL survivors (Po0.05). This study supports an association between CM, CLL and NHL developing in the same patient.
Immunosuppression, exposure to ultraviolet radiation and genetic factors may lead to a host environment that is conducive to the
development of these malignancies.
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Patients with cutaneous malignant melanoma (CM) are at a
significantly increased risk of developing both melanoma (Burden
et al, 1994) and nonmelanoma skin cancer (Swerdlow et al, 1995),
which is most likely because of the shared risk factors of exposure
to ultraviolet radiation and skin type. The association between
CM and other cancer is controversial, but clarification of
these relations may lead to an improved understanding of
aetiology. Several studies reporting an overall increased incidence
of a second primary tumour among CM survivors have been
small hospital-based case series or with short follow-up periods
or included nonmelanoma skin cancer as a second primary
(Adami et al, 1995; Swerdlow et al, 1995; Wassberg et al, 1996;
Bhatia et al, 1999); the type of secondary tumour reported has been
inconsistent (Gutman et al, 1991; Riou et al, 1995; McKenna et al,
2000).
Second cancers including CM have also been well documented
among patients with lymphoid malignancy including non-Hodg-
kin’s lymphoma (NHL) and chronic lymphatic leukaemia (CLL)
(Travis et al 1991, 1992; Adami et al, 1995; Hall et al, 1995; Levi
et al, 1996; Brennan et al, 2000). This has been attributed to the
cytotoxic and immunosuppressive effects of the drug regimens
used to treat these patients (Tucker et al, 1988). We have
previously described a series of CM patients treated by surgery
only, who subsequently developed NHL or CLL, which suggests an
association unrelated to chemotherapy (McKenna et al, 2000).
Using a population-based cancer registry, we examined the
possibility of an association between CM and NHL or CLL by
calculating the risk of CM occurring in patients following a
diagnosis of NHL or CLL, and of NHL or CLL subsequently
developing in CM survivors.
MATERIALS AND METHODS
All patients with a first diagnosis of CM, NHL or CLL (index
cancer) between 1975 and 1997 were identified from the Scottish
national cancer registration system. Patients with an index cancer
were followed through the population-based data set for a
subsequent cancer, either CM, NHL or CLL. Only the first cancer
occurring after the index cancer was included in the analysis to
avoid the potential confounding influence of the second cancer or
its treatment on any subsequent malignancy. Person-years at risk
were calculated as the difference between the date of diagnosis of
the index cancer and either death, date of subsequent cancer or the
end of the follow-up period (December 1997), whichever occurred
first. Person-years of follow-up were stratified by gender, 5-year
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yage groups, and calendar time periods (1975–1979, 1980–1984,
1985–1989, 1990–1994, 1995–1997). The expected number of
cancers for each stratum was calculated by multiplying the person-
years at risk in each stratum by the corresponding sex-, age- and
calendar period-specific incidence rates for Scotland. These were
then added together to obtain the total expected number of
cancers. Overall risk and risk in relation to gender and age at
diagnosis of the index cancer were analysed. Risk in relation to
time since first diagnosis was studied in order to address the
influence of medical surveillance and treatment, which would be
expected to be greater in the first 2 years of follow-up in the former
and greater in the subsequent years for the latter. The standardised
incidence ratio (SIR) was defined as the ratio of the observed to
expected number of cases. The 95% confidence interval and the
test of significance were estimated assuming that the observed
number of cases followed a Poisson distribution.
The logarithm of age- and sex-standardised incidence rates,
directly standardised to the European standard population, were
used to show the changes in incidence rates between 1968 and
1997.
RESULTS
There were 9385 patients identified with CM as the index cancer
with 56195 person-years of follow-up. There were 3465 males and
the median age at diagnosis was 57.3 years. The total number of
observed and expected cases of CLL and NHL developing within
this group is shown in Tables 1 and 2, respectively. These results
are also shown for age, sex and time from CM diagnosis. Overall,
there was a statistically significant 130% increased risk of CLL
recorded following a diagnosis of CM (Table 1). The risk was
greater in males than females, and was significantly raised in the
first 2 years following a diagnosis of CM (Po0.05), although it
remained elevated throughout the follow-up period. The risk was
increased, regardless of age, but this was only statistically
significant for patients aged more than 50 years at diagnosis of
CM (Po0.05), there being very few cases of CM diagnosed under
the age of 50.
There was a nonsignificant 50% higher risk of developing
NHL following a diagnosis of CM which was higher in males
than females (Table 2). The increased risk of NHL following CM
was restricted to the first 2 years of follow-up (Po0.01). The risk of
NHL was greater in patients with a diagnosis of CM before the age
of 50 years, but this was not statistically significant.
There were 4016 patients identified with CLL as the index
cancer with 14450 person-years of follow-up. There were 2351
males and the median age at diagnosis was 72.2 years. The
total number of observed and expected cases of CM developing
within this group is shown in Table 3, also stratified by age,
sex and time from CLL diagnosis. Overall, there was a
nonsignificant 130% increased risk of CM developing following
a diagnosis of CLL which was greater in males than females.
The risk of detecting CM was significantly increased within the
first 2 years of a diagnosis of CLL (Po0.05), and was still greater
than expected 3–10 years later. Only those patients with a
diagnosis of CLL after the age of 50 years had an elevated risk
of developing CM.
There were 13857 patients identified with NHL as the index
cancer with 44999 person-years of follow-up. There were 6760
males and the median age at diagnosis was 67.0 years. The total
number of observed and expected cases of CM developing within
this group is shown in Table 4, also stratified by age, sex and time
from CM diagnosis. Overall, there was a statistically significant
110% increased risk of CM developing in patients with a previous
diagnosis of NHL (Po0.05), although this excess was only
observed in males (Po0.001). The risk of CM developing within
the first 2 years of NHL diagnosis was elevated and remained
higher than expected throughout the period of follow-up, although
not statistically significant. The risk was higher and statistically
significant in patients who had been diagnosed with NHL aged 50
years or older.
Table 1 SIRs for CLL occurring after a diagnosis of malignant melanoma
by sex, age and time from diagnosis of melanoma
Characteristic Observed Expected SIR 95% CI P-value
Total 10.0 4.3 2.3 (1.1, 4.4) o0.05
Male 6.0 2.1 2.9 (1.0, 6.4) o0.05
Female 4.0 2.2 1.8 (0.5, 4.8) n.s.
Age at diagnosis
o50 years 1.0 0.3 3.8 (0.1, 21.4) n.s.
X50 years 9.0 4.0 2.2 (1.0–4.3) o0.05
Time from CM diagnosis
0–2 years 5.0 1.3 4.0 (1.2, 9.3) o0.05
3–10 years 4.0 2.3 1.7 (0.4, 4.5) n.s.
X11 years 1.0 0.7 1.4 (0, 8.2) n.s.
CM=cutaneous malignant melanoma, SIR=standardised incidence rate, CI=confi-
dence interval, n.s.=not significant.
Table 2 SIRs for NHL occurring after a diagnosis of malignant melanoma
by sex, age and time from diagnosis of melanoma
Characteristic Observed Expected SIR 95% CI P-value
Total 18.0 12.2 1.5 (0.0, 2.4) n.s.
Male 9.0 4.4 2.0 (0.9, 3.9) n.s.
Female 9.0 7.8 1.2 (0.5, 2.2) n.s.
Age at diagnosis
o50 years 4.0 1.8 2.2 (0.6, 5.6) n.s.
X50 years 14.0 10.4 1.3 (0.8, 2.4) n.s.
Time from CM diagnosis
0–2 years 10.0 3.6 2.8 (1.3, 5.2) o0.01
3–10 years 6.0 6.9 0.9 (0.3, 1.9) n.s.
X11 years 2.0 1.8 1.1 (0.1, 4.2) n.s.
See Table 1.
Table 3 SIRs for malignant melanoma occurring after a diagnosis of CLL
by sex, age and time from diagnosis of CLL
Characteristic Observed Expected SIR 95% CI P-value
Total 6.0 2.6 2.3 (0.0, 2.4) n.s.
Male 4.0 1.4 2.9 (0.9, 3.9) n.s.
Female 2.0 1.6 1.6 (0.5, 2.2) n.s.
Age at diagnosis
o50 years 0.0 0.1 0.0 (0.0, 0.0) n.s.
X50 years 6.0 2.5 2.4 (0.9, 5.2) n.s.
Time from CLL diagnosis
0–2 years 4.0 1.0 3.9 (1.0, 10.0) o0.05
3–10 years 2.0 1.4 1.4 (0.1, 5.3) n.s.
X11 years 0.0 0.2 0.0 (0.0, 0.0) n.s.
CLL=chronic lymphatic leukaemia, SIR=standardised incidence rate, CI=confidence
interval, n.s.=not significant.
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The rising incidence of both CM and of NHL and CLL over the last
two decades has led some investigators to suggest a common
aetiological association (Figure 1). The rate of increase has been
greatest for CM, which has more than trebled in the last 20 years.
This rise has been attributed to increasing levels of exposure to
ultraviolet radiation although the dosage and pattern of exposure
implicated in its development are unclear (Gilchrest et al, 1999).
Apart from the acquired immunodeficiency syndrome and an
expanding population of transplant recipients on immunosup-
pressive therapy, the increasing incidence of lymphoproliferative
disorders has remained unexplained (Bray et al, 2001). In this
study, we found an increased risk of both NHL and CLL following
a diagnosis of CM and vice versa which was statistically significant
for CLL following a diagnosis of CM and for CM in NHL survivors.
There are several theoretical explanations for the development
of CM and CLL or NHL in the same patient. Chronic
immunosuppression is an established risk factor for the develop-
ment of both lymphoid malignancy and skin cancer. An increase in
CM has been reported following Hodgkin’s (Tucker et al, 1988)
and non-Hodgkin’s lymphoma (Levi et al, 1996), CLL (Travis et al,
1992), renal transplantation (Greene et al, 1981), immunosuppres-
sive therapy (Kinlen, 1985) and among those with genetically
determined immunodeficiency diseases (Spector et al, 1978). CM
that develop in immunosuppressed patients tends to originate
from dysplastic naevi, are more deeply invasive with marked
depression of a host lymphocyte–macrophage response and have
a poorer prognosis (Tucker et al, 1988). Acquired or iatrogenic
immunosuppression may impair cell-mediated immunity such
that tumour-specific lymphocytes are unable to maintain an
effective tumour surveillance system. The cytotoxic and immuno-
suppressive effects of the chemotherapeutic regimens used in the
treatment of NHL patients could explain the higher risk for CM in
NHL survivors as in our study. The risk of CM in CLL patients and
vice versa was identical, consistent with the potentially indolent
course of CLL, which usually presents in elderly patients and often
requires no treatment (Rozman et al, 1997). Moreover, patients
with NHL and CLL exhibit a variety of immunological defects that
may also increase their risk of CM in the absence of any treatment
effect (Vanhaelen and Fisher, 1982).
The power to detect a statistically significant excess risk of a
second cancer in patients whose index malignancy was diagnosed
before the age of 50 years was limited by relatively small numbers
of index cases below this age cutoff. Nevertheless, the higher risk of
CM in patients with a diagnosis of NHL or CLL after the age of 50
years may be a result of cumulative exposure to ultraviolet
radiation followed by immunosuppression as a consequence of
NHL, CLL or its treatment. The much higher risk of CM in male
NHL and CLL patients is noteworthy and has been recorded in
other studies (Travis et al, 1991; 1992; Tsao et al, 2002). We have
no evidence that males are more aggressively treated than females
or are more susceptible to developing skin cancer as a
consequence of the treatment used for these patients.
The relative risk of CM was highest in the first 2 years following
the diagnosis of either NHL or CLL, and remained elevated
throughout in NHL patients. The higher SIR early on after NHL or
CLL diagnosis suggests a possible detection bias because of
increased medical surveillance of patients with malignancy.
Although this may have resulted in a small increase in the overall
SIR, the main effect of this bias would be to bring forward in time
the diagnosis of some cases of CM that may have gone undetected
until several years later.
Following a diagnosis of CM, there was a significant 2.3-fold
increased risk of CLL, which was greatest in the first 2 years
following the CM and was higher in males than females (Table 1).
Similarly, there was a 50% increased risk of NHL in CM survivors,
which was significant in the first two years of follow-up and which
was also higher in males (Table 2). The significantly higher risk of
CLL developing after the age of 50 years may be in keeping with
the average age of onset of the CLL of 70 years (Rozman et al,
Table 4 SIRs for malignant melanoma occurring after a diagnosis of NHL
by sex, age and time from diagnosis of NHL
Characteristic Observed Expected SIR 95% CI P-value
Total 14.0 6.6 2.1 (1.2, 3.6) o0.05
Male 10.0 2.6 3.8 (1.8, 7.0) o0.001
Female 4.0 4.0 1.0 (0.3, 2.6) n.s.
Age at diagnosis
o50 years 2.0 1.1 1.8 (0.2, 6.4) n.s.
X50 years 12.0 5.5 2.2 (1.1, 3.9) o0.05
Time from NHL diagnosis
0–2 years 6.0 2.6 2.3 (0.8, 5.1) n.s.
3–10 years 7.0 3.4 2.1 (0.8, 4.3) n.s.
X11 years 1.0 0.7 1.5 (0.0, 8.8) n.s.
NHL=non-Hodgkin’s lymphoma, SIR=standardised incidence rate, CI=confidence
interval, n.s.=not significant.
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Figure 1 Age- and sex-standardised incidence rates for selected cancers: 1968–1997 European age-standardised rates per 100000 population.
CM¼cutaneous malignant melanoma, CLL¼chronic lymphatic leukaemia, NHL¼non-Hodgkin’s lymphoma.
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population-based cancer registry studies, which have shown an
increased risk of 1.4–2.0 for NHL and CLL following CM (Adami
et al, 1995; Hall et al, 1995; Wassberg et al, 1996; Goggins et al,
2001). Although we do not have any information on treatment, it is
unlikely that either radiotherapy or chemotherapy contributed to
the development of CLL or NHL in these patients as surgery is the
main therapeutic intervention for CM. Whether these patients have
a host environment conducive to the development of both CM and
lymphoid malignancy remains to be determined. Several tumour-
related immunodeficiency mechanisms, mediated by the neoplasm
itself, have been identified and appear to be responsible for
inhibiting recognition and destruction of tumour cells in these
patients. Persistent suppressor T-cell activity has been described in
long-term survivors with lymphoma (Vanhaelen and Fisher, 1982)
and enhanced suppressor T-cell activity has been demonstrated in
patients with CM, which disappears with removal of the tumour
(Werkmeister et al, 1981). Such a mechanism may explain an
aetiological link between melanoma and the occurrence of
lymphoid malignancy in the same patient.
In addition to its mutagenic effect, ultraviolet radiation (UV) has
an immunosuppressive effect both systemically and locally in the
skin (Cooper et al, 1992). Several epidemiological studies have
linked the parallel rise in incidence of lymphoid disorders and skin
cancer to increased levels of UV exposure (Adami et al, 1995, 1999;
McMichael and Giles, 1996), although this has not been confirmed
by others (Hartge et al, 1996; Freedman et al, 1997). An excess risk
of both CM and lymphoid malignancy has been reported in higher
socioeconomic, white-collar workers (Schumacher and Delzell,
1988; MacKie and Hole, 1996), possibly because of increased
recreational sun exposure. In a geographically based study in
England and Wales, the incidence of NHL was significantly
associated with high levels of UV exposure, even after correction
for social class and occupation (Bentham, 1996). Other studies
using skin cancer as a marker of UV exposure have shown a
positive correlation between lymphoid disorders and skin cancer,
including CM (Adami et al, 1995; Hall et al, 1995; Tsao et al, 2002).
Both CM and lymphoid malignancy have a strong genetic
component. The p16 gene, which inhibits the cyclin-dependent
kinase CDNK4, has been proposed as a candidate for a tumour
suppressor gene located on chromosome 9p21 (Kamb et al, 1994).
Mutations and deletions of this gene have been reported in a wide
variety of human cancers, including familial and sporadic cases of
CM (Healy et al, 1996) as well in several different types of
leukaemia and lymphoma (Ogawa et al, 1994). Molecular screening
of tissue samples for inactivation of this gene in patients who
develop both CM and lymphoid malignancy may determine
whether it is important in the common pathogenesis of these
tumours.
In summary, we found an increased risk of both NHL and CLL
following a diagnosis of CM and vice versa that suggests an
association. In addition to treatment effects and surveillance bias,
further study is required to determine what role, if any, shared
environmental or genetic factors play in this association.
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